Loading…
Loading…
Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Corp. (CSE:UDOC)(FRA:L7T)(OTCQB:UDOCF) ("UniDoc" or the "Company"), a company developing eHealth solutions, is pleased to announce that it has signed a non-exclusive and non-binding memorandum of understanding (the "MOU") with Ventripoint Diagnostics Ltd. (TSXV:VPT) (OTC:VPTDF) ("Ventripoint") to evaluate a potential collaboration focused on remote cardiac assessment and cardiovascular screening.
TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound images into three-dimensional cardiac measurements.
Toronto, Ontario – The Newswire – August 7, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") (TSXV:VPT; OTC:VPTDF) announces that it incorrectly granted 7,246,250 stock options of the Company to various officers, employees and consultants of the Company during the period of February 27, 2025 to May 27, 2026 as the Company did not obtain the necessary annual shareholder approval for the Company's stock option plan. The Company had previously cancelled 250,000 option grants which will not be re-granted and effective June 30, 2026 has cancelled 4,301,250 option grants (the “ Cancelled Options ”), which included 1,000,000 options granted to an officer of the company. The Company has re-granted 3,151,250 of the cancelled options including 1,000,000 to an officer of the company and granted 3,241,500 annual incentive option grants to directors, officers, employees and consultants of the Company, which included 1,500,000 to officers and directors, at the current market price on July 8, 2026 under the stock option plan, which was approved at the Company's recent shareholder meeting on May 27, 2026. A total of 6,392,750 were granted at an exercise price of $0.095 for terms of 2 to 10 years and vesting immediately to over 3 years. The company has 13.7 million options issued at a volume-weighted average exercise price of $0.16. and 5.0 million options available for future grants. The Company also announces that the grant and exercise of an aggregate of 2,695,000 stock options to various employees and consultants of the Company will be treated as a non-brokered private placement at prices ranging from $0.10 to $0.12, with an effective closing date of July 29, 2026, subject to TSXV acceptance.
Proposed collaboration would combine UniDoc Health Cubes and connected-care infrastructure with Ventripoint's AI-enabled VMS+™ platform in a hub-and-spoke care model Toronto, Ontario – TheNewswire – August 5, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT; OTC:VPTDF) a leader in AI-powered cardiac imaging, is pleased to announce that it has signed a memorandum of understanding ("MOU") with UniDoc Health Corp. ("UniDoc") to evaluate a potential collaboration focused on remote cardiac assessment and cardiovascular screening.
Toronto, Ontario – July 29, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV: VPT; OTC: VPTDF), a leader in AI-powered cardiac imaging, today announced the appointment of Dr. Philip M. Toleikis to its Board of Directors, adding extensive public company leadership, capital markets expertise, and medical technology commercialization experience as the Company accelerates the global expansion of its VMS+ cardiac imaging platform. Dr. Toleikis is a seasoned life sciences executive with a proven track record of building innovative healthcare companies, securing capital, developing strategic partnerships, and creating shareholder value. His appointment further strengthens Ventripoint's governance as the Company advances commercial execution and positions itself for growth.
Toronto, Ontario – TheNewswire - July 22, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of 601,115 common shares (“ Shares ”) for the payment of an aggregate of $72,143 of interest owing on certain outstanding Convertible Debentures issued by the Corporation on May 10, 2024, June 28, 2024 and December 16, 2024 . The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of ($0.12), subject to the approval of TSXV, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation. About Ventripoint Diagnostics Ltd.
Pioneering Medical AI Company Moves to Increase Awareness of VMS+ System and Proprietary Knowledge Based Reconstruction Technology Toronto, Ontario – TheNewswire – July 22, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, is pleased to announce that it has engaged More Capital Ltd. ("More Capital"), a Toronto, Ontario-based private investment and strategic advisory firm, under a strategic growth and advisory agreement focused on commercial partnerships, market expansion and broader awareness of the Company's technology, subject to acceptance by the TSX Venture Exchange ("TSX-V").
Ventripoint's VMS+ platform to be evaluated alongside a second AI technology in a landmark NHS study exploring earlier detection of chemotherapy-related heart damage Toronto, Ontario – TheNewswire – July 20, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in the application of artificial intelligence to echocardiography, today announced that its VMS+ technology has been selected for use in AIRES (Artificial Intelligence Reconstruction of Echocardiography Study), a newly launched clinical research study at The Royal Wolverhampton NHS Trust (RWT) in the United Kingdom.
No recent filings indexed.